JP MORGAN/PUT/VERTEX PHARMACEUTICALS/310/0.1/17.01.25

JP MORGAN/PUT/VERTEX PHARMACEUTICALS/310/0.1/17.01.25 Share Price

DE000JL09QA0

Market Closed - Börse Stuttgart 12:19:41 31/05/2024 pm IST
0.45 ^EUR	-10.00%

Current month	-50.00%
1 month	-50.00%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes

Chart VERTEX PHARMACEUTICALS INCORPORATED

Chart JP MORGAN/PUT/VERTEX PHARMACEUTICALS/310/0.1/17.01.25

Latest news about VERTEX PHARMACEUTICALS INCORPORATED

BMO Capital Adjusts Price Target on Vertex Pharmaceuticals to $500 From $480	31/05	MT
Vertex Pharmaceuticals Insider Sold Shares Worth $1,478,068, According to a Recent SEC Filing	31/05	MT
Vertex Pharmaceuticals Insider Sold Shares Worth $715,205, According to a Recent SEC Filing	30/05	MT
Vertex Pharmaceuticals Insider Sold Shares Worth $3,168,704, According to a Recent SEC Filing	25/05	MT

More news

Quotes 5-day view

Date	Price	Change
31/24/31	0.45	-10.00%
30/24/30	0.5	+21.95%
29/24/29	0.41	+24.24%
28/24/28	0.33	-5.71%
27/24/27	0.35	-7.89%

Delayed Quote Börse Stuttgart

Last update May 31, 2024 at 12:19 pm IST

More quotes

Static data

Product type	Warrants
Buy / Sell	PUT
Underlying	VERTEX PHARMACEUTICALS INCORPORATED
Issuer	J.P. Morgan
WKN	JL09QA
ISIN	DE000JL09QA0
Date issued	12/04/2023
Strike	310 $
Maturity	17/01/2025 (230 Days)
Parity	10 : 1
Emission price	3.66 €
Emission volume	N/A
Settlement	règlement en espèces
Currency	EUR

Technical Indicators

Highest since issue	4.35 €
Lowest since issue	0.33 €
Delta	-0.08x
Omega	5.570
Premium	33.37x
Gearing	68.8x
Moneyness	0.6808
Difference Strike	-145.3 $
Difference Strike %	-46.88%
Spread	0.5 €
Spread %	58.14%
Theoretical value	0.6100
Implied Volatility	42.98 %
Total Loss Probability	85.47 %
Intrinsic value	0.000000
Present value	0.6100
Break even	303.38 €
Theta	-0.03x
Vega	0.05x
Rho	-0.03x

Company Profile

Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases. Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).

Sector

More about the company

Ratings for Vertex Pharmaceuticals Incorporated

Trading Rating

Investor Rating

ESG Refinitiv

B+

More Ratings

Consensus: Vertex Pharmaceuticals Incorporated

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

455.3 USD

Average target price

463.5 USD

Spread / Average Target

+1.80%

Consensus